MarketLens
Sign Up

Is Bionano Genomics' Optical Genome Mapping a Game-Changer for Genetic Diagnostics

6 months ago
SHARE THIS ON:

Is Bionano Genomics' Optical Genome Mapping a Game-Changer for Genetic Diagnostics

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News•3 weeks ago

BillionToOne: New Kid On The Molecular Diagnostics Block Poised To Take Share

BillionToOne is disrupting molecular diagnostics with proprietary smNGS technology, reaching a $5.2B market cap. Its Unity Complete prenatal test bypasses paternal testing and expands to 130 genes, wh...
Stock News•2 months ago

Bionano Announces Three New Peer-Reviewed Studies Demonstrate Clinical Value of Bionano's Optical Genome Mapping Across Myelodysplastic Syndromes and Acute Myeloid Leukemia

Three independent studies report that Bionano's optical genome mapping detects clinically significant genomic alterations missed by conventional cytogenetics in MDS, AML, and therapy-related myeloid n...
Stock News•2 months ago

GeneDx and Beren Therapeutics Launch NPC GenomeComplete to Improve Diagnosis of Niemann-Pick Disease Type C

GeneDx and Beren Therapeutics launched NPC GenomeComplete, a diagnostic test for Niemann-Pick disease type C, aiming to improve detection and shorten time to diagnosis for patients.

Breaking News

View All →

Top Headlines

View More →
Press Release•34 minutes ago

Advanced Micro Devices, Inc. Investigated on Behalf of Investors with $100,000 or More in Losses - Contact the DJS Law Group to Discuss Your Rights – AMD

Stock News•1 hour ago

Methuselah Advisors Issues Open Letter to the Board of Directors of NVIDIA Corporation

Stock News•1 hour ago

Stock Market Today, Nov. 20: Amazon Shares Slide on AI and Mega-Cap Tech Sell-Off

Stock News•1 hour ago

AMD Investors Have Opportunity to Join Advanced Micro Devices, Inc. Fraud Investigation with SBS Law

Stock News•1 hour ago

Nvidia Plunges as SEC Probe Deepens AI Market Selloff | Closing Bell